Here is an interesting article by Dr Hassan reporting the results of a phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009.
Mesothelin is expressed on the surface of many different cancer cells, particularly in the epithelioid type of mesothelioma.  Mesothelin provides a target for anti-mesothelin antibodies.  At least 2 treatment strategies are being tested currently, the SS1P (a recombinant immunotoxin with anti-mesothelin Fv linked to a truncated Pseudomonas exotoxin) and the MORAb-009 (a high-affinity monoclonal antibody, a chimera between mouse Fv and human IgG1/k Fc).  The MORAb-009 may …